When a Biologic Worked and Then Stopped: A Guide to Secondary Loss of Response

A biologic that worked well for a year or two and then quietly stopped holding the line is one of the more destabilizing experiences in inflammatory bowel disease. The clinical term for it is secondary loss of response, meaning the drug produced a genuine initial benefit and then that benefit faded. It is common. In patients treated with anti-tumor necrosis factor, or anti-TNF, therapy, up to half of patients lose response over time, at an annual rate of roughly 5 to 20 percent. The useful news is that this situation has a defined workup. Symptoms returning does not automatically mean the drug is finished, and it does not automatically mean the next step is a new prescription. What follows is the sequence most gastroenterologists work through, and what each result actually changes.

First, Confirm the Symptoms Are Coming From Inflammation

Returning diarrhea, urgency, or cramping can come from active disease, but they can also come from causes that a drug change will not fix. Infection is the first thing to exclude. All IBD patients presenting with worsening diarrhea or symptoms of colitis should be tested for toxigenic Clostridioides difficile in the stool, which is a leading trigger of what looks like a flare. Beyond infection, the standard list of mimics includes irritable bowel syndrome, small bowel bacterial overgrowth, and bile acid malabsorption, none of which respond to escalating a biologic.

Objective markers settle the question. American Gastroenterological Association guidance treats fecal calprotectin under 150 micrograms per gram and C-reactive protein under 5 milligrams per liter as normal, and recommends endoscopic assessment of disease activity rather than empiric treatment adjustment when symptoms and biomarkers disagree. That recommendation matters because it protects patients from abandoning a working drug on the basis of symptoms alone.

What Therapeutic Drug Monitoring Measures

Once inflammation is confirmed, the next test is therapeutic drug monitoring, usually shortened to TDM. It measures two things from a blood draw: the trough concentration of the drug, meaning the level in your blood immediately before the next dose, and whether your immune system has produced anti-drug antibodies against it. The American Gastroenterological Association suggests reactive therapeutic drug monitoring to guide treatment changes in adults with active IBD on anti-TNF agents, a recommendation issued in its 2017 guideline on therapeutic drug monitoring in inflammatory bowel disease. The 2025 American College of Gastroenterology ulcerative colitis guideline takes the same position, recommending measurement of serum drug levels and antidrug antibodies when patients with moderate-to-severe UC lose response to anti-TNF therapy.

Target ranges vary by drug and by what you are trying to achieve. One practical review describes infliximab targets of roughly 3 to 5 micrograms per milliliter for clinical disease control and 8 to 12 micrograms per milliliter for endoscopic remission, while other maintenance frameworks cite 3 to 7 milligrams per liter for infliximab and 5 to 10 milligrams per liter for adalimumab. Ranges differ between laboratory assays, so results should be compared against the range your own lab reports.

Reading the Result Pattern

TDM results sort into a small number of patterns, and each points somewhere different. A published algorithm maps them directly: a low drug level with negative or low antibodies calls for dose escalation, a low drug level with high antibodies points toward switching within the same class, and an adequate drug level with persistent inflammation suggests the disease is being driven by a pathway the drug does not block, which makes switching out of class appropriate.

Antibody formation is the mechanism behind a large share of these cases. Historical data report that up to 73 percent of infliximab patients and up to 35 percent of adalimumab patients develop persistent anti-drug antibodies, with about a third of those patients losing response, typically within 12 months of starting treatment. Low-level antibodies are common and often transient, so a single positive result is a data point rather than a verdict.

Dose Optimization Before Switching

When the drug level is low and antibodies are absent, the drug has usually been cleared faster than expected rather than defeated. Increasing the dose or shortening the interval often restores control. When antibodies are the problem, adding an immunomodulator can suppress them. In one study, 77 percent of patients with immunogenic loss of response reached undetectable antibody levels, higher drug concentrations, and regained clinical response after an immunomodulator was added.

Dose optimization is also well documented for the newer classes. A meta-analysis found that loss of response to vedolizumab occurred at 47.9 per 100 person-years in Crohn's disease and 39.8 per 100 person-years in ulcerative colitis, and that dose intensification restored response in 53.8 percent of secondary non-responders. A separate real-world review reported that 196 of 395 patients, or 49.6 percent, responded within 54 weeks of escalating vedolizumab maintenance dosing. For ustekinumab in Crohn's disease, dose escalation or reinduction recaptured clinical response in 55 percent of patients and endoscopic response in 61 percent.

Choosing the Next Drug If Optimization Fails

If the level is already therapeutic and inflammation persists, more of the same drug is unlikely to help, and the decision moves to a different mechanism. Prior biologic exposure changes which options perform best. The 2025 AGA evidence synthesis for Crohn's disease found moderate-to-high certainty evidence supporting adalimumab, ustekinumab, risankizumab, guselkumab, and upadacitinib for inducing remission in previously treated patients, with lower certainty for vedolizumab and mirikizumab. Within-class switching still has a place when antibodies rather than mechanism explain the failure, since a second anti-TNF can work when the first was neutralized. Long-term data show that optimization strategies can overcome immunogenicity and preserve anti-TNF therapy in a meaningful share of patients.

Bringing a dated record to the appointment shortens all of this considerably. Note when symptoms changed, the dates of every infusion or injection including any delayed or missed doses, recent calprotectin and CRP values, and any drug level or antibody results already drawn. That record turns an appointment spent reconstructing history into one spent choosing between dose escalation, an added immunomodulator, and a change of mechanism.